PPARG and gastric cancer: Rosiglitazone was found to suppress metastatic potential in gastric cancer, and the enhanced activity of PPARγ resulted in increased direct transcriptional activation of cellular adhesion molecule 3, which inhibits the migration and invasion of gastric cancer cells [333,334].